Sad news to report.
The Rett patient who was hospitalized with a critical immune reaction to $NGNE 's gene therapy has died.
A reminder that participants in these studies put themselves at risk in the hope for a cure not only for themselves but for others.
www.sec.gov/ix?doc=/Arch...
The Rett patient who was hospitalized with a critical immune reaction to $NGNE 's gene therapy has died.
A reminder that participants in these studies put themselves at risk in the hope for a cure not only for themselves but for others.
www.sec.gov/ix?doc=/Arch...
https://www.sec.gov/ix?doc=/Archives/edgar/data/1404644/000140464424000109/ngne-20241120.htm
<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" lang="...
www.sec.gov
November 21, 2024 at 9:27 PM
Sad news to report.
The Rett patient who was hospitalized with a critical immune reaction to $NGNE 's gene therapy has died.
A reminder that participants in these studies put themselves at risk in the hope for a cure not only for themselves but for others.
www.sec.gov/ix?doc=/Arch...
The Rett patient who was hospitalized with a critical immune reaction to $NGNE 's gene therapy has died.
A reminder that participants in these studies put themselves at risk in the hope for a cure not only for themselves but for others.
www.sec.gov/ix?doc=/Arch...
🚨 $NGNE
McMinn Rachel (Chief Executive Officer) reported special transactions (Non-P/S).
McMinn Rachel (Chief Executive Officer) reported special transactions (Non-P/S).
SEC Filing: NGNE
Click to view the official SEC document.
www.sec.gov
October 2, 2026 at 6:49 PM
🚨 $NGNE
McMinn Rachel (Chief Executive Officer) reported special transactions (Non-P/S).
McMinn Rachel (Chief Executive Officer) reported special transactions (Non-P/S).
Los técnicos de rayos no son gente sociable. Se imaginó diciendo a la señora "tiene que quitarse el sujetador" y solo le salio "NGÑE".
May 31, 2026 at 12:30 PM
Los técnicos de rayos no son gente sociable. Se imaginó diciendo a la señora "tiene que quitarse el sujetador" y solo le salio "NGÑE".
Neurogene ($NGNE): new 11.1% holder
Jennison Associates: 0 → 11.1% (about $59M)
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 6
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Jennison Associates: 0 → 11.1% (about $59M)
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 6
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Jennison Associates LLC: 11.1% of Neurogene ($NGNE)
Filed Oct 6. Who filed, the stake, and how it changed.
elixstocks.com
October 6, 2026 at 5:51 PM
Neurogene ($NGNE): new 11.1% holder
Jennison Associates: 0 → 11.1% (about $59M)
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 6
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Jennison Associates: 0 → 11.1% (about $59M)
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 6
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Neurogene ($NGNE): new 11.1% holder
Jennison Associates: 0 → 11.1% (about $59M)
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 6
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Jennison Associates: 0 → 11.1% (about $59M)
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 6
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Jennison Associates LLC: 11.1% of Neurogene ($NGNE)
Schedule 13G filed Oct 6. Who filed, the stake, and how it changed.
elixstocks.com
October 6, 2026 at 5:51 PM
Neurogene ($NGNE): new 11.1% holder
Jennison Associates: 0 → 11.1% (about $59M)
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 6
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Jennison Associates: 0 → 11.1% (about $59M)
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 6
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
#NGNE Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://www.stocktitan.net/news/NGNE/neurogene-announces-inducement-grants-under-nasdaq-listing-rule-5635-mnjwvjg9ye51.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/NGNE/neurogene-announces-inducement-grants-under-nasdaq-listing-rule-5635-mnjwvjg9ye51.html?utm_source=stocktitan-bluesky&utm_medium=social
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 5, 2026 at 8:01 PM
#NGNE Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://www.stocktitan.net/news/NGNE/neurogene-announces-inducement-grants-under-nasdaq-listing-rule-5635-mnjwvjg9ye51.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/NGNE/neurogene-announces-inducement-grants-under-nasdaq-listing-rule-5635-mnjwvjg9ye51.html?utm_source=stocktitan-bluesky&utm_medium=social
$NGNE ceases further development of high dose of its gene therapy for Rett due to a life-threatening toxicity.
This is the same serious side effect that management downplayed last week.
www.businesswire.com/news/home/20...
This is the same serious side effect that management downplayed last week.
www.businesswire.com/news/home/20...
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neu
www.businesswire.com
November 18, 2024 at 12:07 PM
$NGNE ceases further development of high dose of its gene therapy for Rett due to a life-threatening toxicity.
This is the same serious side effect that management downplayed last week.
www.businesswire.com/news/home/20...
This is the same serious side effect that management downplayed last week.
www.businesswire.com/news/home/20...
Breaking News: ( NASDAQ: #NGNE ) Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Shareholders to Inquire about Securities Investigation
#StockMarket #News
#StockMarket #News
November 25, 2024 at 8:35 PM
From me, last week:
$NGNE and the race to the bottom of gene therapy
www.statnews.com/2024/11/14/n...
$NGNE and the race to the bottom of gene therapy
www.statnews.com/2024/11/14/n...
Neurogene and the race to the bottom of gene therapy
At Neurogene, the developer of a gene therapy for Rett syndrome, expediency seems to be the priority, @adamfeuerstein writes.
www.statnews.com
November 18, 2024 at 12:07 PM
From me, last week:
$NGNE and the race to the bottom of gene therapy
www.statnews.com/2024/11/14/n...
$NGNE and the race to the bottom of gene therapy
www.statnews.com/2024/11/14/n...
The gang is watching the countdown!
June 1, 2026 at 5:15 PM
The gang is watching the countdown!
Tá neart lámhscríbhinní Gaeilge mór le rá ag UCD & Cnuasach Bhéaloideas Éireann freisin, atá aitheanta ag UNESCO. #SnaG2025
Tá ról lárnach ag an Ollscoil in athbheochan agus caomhnú na Gaeilge. Breathnaigh ar an ngné-alt faoi Thaighde na Gaeilge in UCD!
ucd.ie/research/spo...
Tá ról lárnach ag an Ollscoil in athbheochan agus caomhnú na Gaeilge. Breathnaigh ar an ngné-alt faoi Thaighde na Gaeilge in UCD!
ucd.ie/research/spo...
March 10, 2025 at 11:29 AM
Tá neart lámhscríbhinní Gaeilge mór le rá ag UCD & Cnuasach Bhéaloideas Éireann freisin, atá aitheanta ag UNESCO. #SnaG2025
Tá ról lárnach ag an Ollscoil in athbheochan agus caomhnú na Gaeilge. Breathnaigh ar an ngné-alt faoi Thaighde na Gaeilge in UCD!
ucd.ie/research/spo...
Tá ról lárnach ag an Ollscoil in athbheochan agus caomhnú na Gaeilge. Breathnaigh ar an ngné-alt faoi Thaighde na Gaeilge in UCD!
ucd.ie/research/spo...
'Ngne 'a fàa e se sta!🤮
February 1, 2025 at 2:23 PM
'Ngne 'a fàa e se sta!🤮
Here is a song we wrote for the people of Gaza:
www.youtube.com/watch?v=ngne...
www.youtube.com/watch?v=ngne...
The Beauty in the Beast by The Oxbow Estate
YouTube video by The Oxbow Estate
www.youtube.com
June 25, 2025 at 9:35 PM
Here is a song we wrote for the people of Gaza:
www.youtube.com/watch?v=ngne...
www.youtube.com/watch?v=ngne...
www.thejournal.ie/udaras-na-ga...
D’inis Údarás do The Journal go bhfuil cúram orthu mar eagraíocht thar ceann an Rialtais forbairt a dhéanamh ar an ngné Intleacht Shaorga de Phlean Digiteach na Gaeilge 2023-2027.
----
Má tá leithéidí an comórtas seo sa phlean, tá an plean go hainnis
D’inis Údarás do The Journal go bhfuil cúram orthu mar eagraíocht thar ceann an Rialtais forbairt a dhéanamh ar an ngné Intleacht Shaorga de Phlean Digiteach na Gaeilge 2023-2027.
----
Má tá leithéidí an comórtas seo sa phlean, tá an plean go hainnis
'Masla é sin ar an rud is ealaín ann': frithtonn faoi chomórtas intleachta saorga an Údaráis
Chosain Údarás na Gaeltachta a gcinneadh an comórtas a chur ar siúl.
www.thejournal.ie
December 23, 2025 at 9:44 PM
www.thejournal.ie/udaras-na-ga...
D’inis Údarás do The Journal go bhfuil cúram orthu mar eagraíocht thar ceann an Rialtais forbairt a dhéanamh ar an ngné Intleacht Shaorga de Phlean Digiteach na Gaeilge 2023-2027.
----
Má tá leithéidí an comórtas seo sa phlean, tá an plean go hainnis
D’inis Údarás do The Journal go bhfuil cúram orthu mar eagraíocht thar ceann an Rialtais forbairt a dhéanamh ar an ngné Intleacht Shaorga de Phlean Digiteach na Gaeilge 2023-2027.
----
Má tá leithéidí an comórtas seo sa phlean, tá an plean go hainnis
Ní bhíonn ainmfhocail sa chomhréir sin san iolra i nG an lae inniu de ghnáth. Mar shampla:
Beidh a ngné go holc. Beidh sé sin ar a gceann.
Agus sa Bhíobla:
Beidh a ngné go holc. Beidh sé sin ar a gceann.
Agus sa Bhíobla:
June 13, 2026 at 4:41 PM
Ní bhíonn ainmfhocail sa chomhréir sin san iolra i nG an lae inniu de ghnáth. Mar shampla:
Beidh a ngné go holc. Beidh sé sin ar a gceann.
Agus sa Bhíobla:
Beidh a ngné go holc. Beidh sé sin ar a gceann.
Agus sa Bhíobla:
"Eur Ngne" is almost too good to be a Star Wars name
February 20, 2025 at 1:32 PM
"Eur Ngne" is almost too good to be a Star Wars name
That jesus had reincarnated as a Nimodian Woman named Eur Ngne in a Galaxy Far Far Away
February 20, 2025 at 1:30 PM
That jesus had reincarnated as a Nimodian Woman named Eur Ngne in a Galaxy Far Far Away
Breaking News: ( NASDAQ: #NGNE ) Neurogene Announces Oversubscribed $200 Million Private Placement
#StockMarket #News
#StockMarket #News
November 4, 2024 at 3:55 PM
Breaking News: ( NASDAQ: #NGNE ) Neurogene Announces Oversubscribed $200 Million Private Placement
#StockMarket #News
#StockMarket #News
NGNE
- Closed at $46.07 on Fri 1 Nov
- Raised $200m PIPE at $50 on Mon 4 Nov
- Touched 52-week high of $74.49 on Fri 8 Nov
- Now trading ~$41 on Mon 11 Nov
- Closed at $46.07 on Fri 1 Nov
- Raised $200m PIPE at $50 on Mon 4 Nov
- Touched 52-week high of $74.49 on Fri 8 Nov
- Now trading ~$41 on Mon 11 Nov
November 12, 2024 at 2:58 PM
NGNE
- Closed at $46.07 on Fri 1 Nov
- Raised $200m PIPE at $50 on Mon 4 Nov
- Touched 52-week high of $74.49 on Fri 8 Nov
- Now trading ~$41 on Mon 11 Nov
- Closed at $46.07 on Fri 1 Nov
- Raised $200m PIPE at $50 on Mon 4 Nov
- Touched 52-week high of $74.49 on Fri 8 Nov
- Now trading ~$41 on Mon 11 Nov
#NGNE Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
https://www.stocktitan.net/news/NGNE/neurogene-reports-second-quarter-2026-financial-results-and-xlbbfdns2sb9.html
https://www.stocktitan.net/news/NGNE/neurogene-reports-second-quarter-2026-financial-results-and-xlbbfdns2sb9.html
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene (Nasdaq: NGNE) reported second quarter 2026 results and progress on its NGN-401 Rett syndrome gene therapy. Phase 1/2 data (N=10) showed 100% of participants improved on CGI-I and gained ≥1 developmental milestone, averaging 4.7 milestones, with continued gains through 30 months and no plateau or milestone loss as of June 16, 2026.According to Neurogene, 7 of 10 participants gained ≥2 milestones and improved across ≥2 Rett domains, with significant benefits on RSGMS and RSHFS (p<0.001). NGN-401 was generally well-tolerated at 1E15 vg in 35 participants across trials as of August 10, 2026. All 25 Embolden registrational trial participants have been dosed, with topline data expected in 2H 2027, and a PPQ manufacturing campaign initiated in July 2026 to support a planned BLA, with PPQ runs targeted for completion by year-end 2026.The company completed an oversubscribed follow-on offering for approximately $144 million in gross proceeds. Cash, cash equivalents and short-term investments were $225.4 million at June 30, 2026, rising to a pro forma $360.2 million with July offering proceeds, which Neurogene expects to fund operations into 1Q 2029. Second quarter 2026 R&D and G&A expenses were $25.5 million and $11.2 million, respectively, and net loss was $34.5 million.
www.stocktitan.net
August 11, 2026 at 11:30 AM
#NGNE Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
https://www.stocktitan.net/news/NGNE/neurogene-reports-second-quarter-2026-financial-results-and-xlbbfdns2sb9.html
https://www.stocktitan.net/news/NGNE/neurogene-reports-second-quarter-2026-financial-results-and-xlbbfdns2sb9.html